Haleon’s 2.1% Sales Growth Puts £500 M Savings Goal in Doubt
Haleon reported organic revenue growth of just 2.1% in the latest quarter, missing its 4%–5% mid-term target range. Analysts warn that the plan to deliver £500 million in annual cost savings by 2027 and expand margins by 100 basis points appears increasingly unattainable under current sales trends.
1. Quarterly Sales Performance
Haleon’s latest quarter saw organic net revenue growth slow to 2.1%, driven by weaker demand in its oral health and pain relief divisions. This underperformance marks the third consecutive quarter below the company’s 4%–5% target range, raising concerns among investors.
2. Mid-Term Targets Under Scrutiny
The company’s ambition to achieve £500 million in annual cost savings by 2027 and expand operating margin by 100 basis points is now viewed as optimistic. Analysts note that with current sales momentum, management may need to revise growth forecasts or accelerate restructuring efforts to hit these goals.